Plain-English translation of NCT03379909 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication commonly used for diabetes, might help treat early-stage bladder cancer when taken by mouth. Researchers want to see if the medication can shrink or eliminate small bladder tumors over a 3-month period. The study will enroll about 49 patients to evaluate how well this treatment works.
Most early-stage bladder cancers are currently treated with surgery or chemicals inserted directly into the bladder. This trial explores whether this medication could offer a simpler, non-invasive option by taking it by mouth instead.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth at a dose of up to 1500 mg twice daily for 3 months. After 3 months, you would return for a cystoscopy procedure (a camera exam of your bladder) under anesthesia, during which doctors will evaluate whether the tumor has shrunk or disappeared and remove any remaining tissue. The study involves multiple visits at a specialized bladder cancer center over this 3-month period.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Netherlands